335 related articles for article (PubMed ID: 30249040)
1. Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
Sayour EJ; Mendez-Gomez HR; Mitchell DA
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249040
[TBL] [Abstract][Full Text] [Related]
2. Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.
Varypataki EM; Silva AL; Barnier-Quer C; Collin N; Ossendorp F; Jiskoot W
J Control Release; 2016 Mar; 226():98-106. PubMed ID: 26876760
[TBL] [Abstract][Full Text] [Related]
3. Drug Delivery for Cancer Immunotherapy and Vaccines.
Batty CJ; Tiet P; Bachelder EM; Ainslie KM
Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
5. Liposome-based immunity-inducing systems for cancer immunotherapy.
Yuba E
Mol Immunol; 2018 Jun; 98():8-12. PubMed ID: 29128232
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
Butt AQ; Mills KH
Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
[TBL] [Abstract][Full Text] [Related]
7. pH-sensitive polymer-modified liposome-based immunity-inducing system: Effects of inclusion of cationic lipid and CpG-DNA.
Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
Biomaterials; 2017 Oct; 141():272-283. PubMed ID: 28704679
[TBL] [Abstract][Full Text] [Related]
8. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
9. VLPs and particle strategies for cancer vaccines.
Ungaro F; Conte C; Quaglia F; Tornesello ML; Buonaguro FM; Buonaguro L
Expert Rev Vaccines; 2013 Oct; 12(10):1173-93. PubMed ID: 24124878
[TBL] [Abstract][Full Text] [Related]
10. Vaccines to treat cancer--an old approach whose time has arrived.
Hellstrom KE; Hellstrom I
J Cell Biochem; 2007 Oct; 102(2):291-300. PubMed ID: 17729239
[TBL] [Abstract][Full Text] [Related]
11. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
12. Liposomes composed of reconstituted membranes for induction of tumor-specific immunity.
Westerman LE; Jensen PE
Methods Enzymol; 2003; 373():118-27. PubMed ID: 14714400
[No Abstract] [Full Text] [Related]
13. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.
Grabbe S; Haas H; Diken M; Kranz LM; Langguth P; Sahin U
Nanomedicine (Lond); 2016 Oct; 11(20):2723-2734. PubMed ID: 27700619
[TBL] [Abstract][Full Text] [Related]
14. pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon-γ gene lipoplex for efficient cancer immunotherapy.
Yuba E; Kanda Y; Yoshizaki Y; Teranishi R; Harada A; Sugiura K; Izawa T; Yamate J; Sakaguchi N; Koiwai K; Kono K
Biomaterials; 2015 Oct; 67():214-24. PubMed ID: 26222284
[TBL] [Abstract][Full Text] [Related]
15. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory colloidal delivery systems for cancer vaccines.
Saupe A; McBurney W; Rades T; Hook S
Expert Opin Drug Deliv; 2006 May; 3(3):345-54. PubMed ID: 16640495
[TBL] [Abstract][Full Text] [Related]
17. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
18. A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy.
Miyabe H; Hyodo M; Nakamura T; Sato Y; Hayakawa Y; Harashima H
J Control Release; 2014 Jun; 184():20-7. PubMed ID: 24727060
[TBL] [Abstract][Full Text] [Related]
19. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
Kobiyama K; Ishii KJ
Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159
[TBL] [Abstract][Full Text] [Related]
20. cRGD target liposome delivery system promoted immunogenic cell death through enhanced anticancer potency of a thymidine conjugate under UVA activation as a cancer vaccine.
Yang R; Wang Z; Yuan Y; Qian T; Zhou Q
Eur J Med Chem; 2019 Apr; 167():499-509. PubMed ID: 30784882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
